One of the an important, albeit rare, fatal case has been reported in the study by Van Oekelen et al. on a case involving a patient with multiple myeloma (MM) who was treated with BCMA-targeting CAR-T cell therapy as part of the CARTITUDE-1 trial [119]. Here, TNFRSF17 is linked to plasma cell myeloma.